Orphina is a biotechnology company at seed stage, focused on preserving and prolonging muscle health.  Our initial clinical gene therapy program is for a rare disease indication of unmet medical need. Our technology allows re-dosing while limiting exposure to vital organs, thereby increasing therapeutic effect and reducing the risk of severe or life-threatening side effects.